title: Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
abstract: BACKGROUND
  Patients with advanced chordoma are often treated with tyrosine kinase inhibitors without any predictive factor to guide decision. We report herein an ancillary analysis of the the Angionext phase II trial (NCT 00874874).
  
  
  RESULTS
  From May 2011 to January 2014, 26 were sampled. The 9-month PFS rate was 72.9% (95%-CI: 45.9-87.9). During sorafenib treatment, a significant increase in PlGF (18.4 vs 43.8 pg/mL, p<0.001) was noted along with a non-significant increase in VEGF (0.7 vs 1.0 ng/mL, p=0.07). VEGF at D1 >1.04 ng/mL (HR=12.5, 95%-CI: 1.37-114, p=0.025) and VEGF at D7 >1.36 ng/mL (HR=10.7, 95%-CI: 1.16-98, p=0.037) were associated with shorter PFS. The 9-month PFS rate was 92.3% (95%-CI: 56.6-98.9) when VEGF at D1 was ≤1.04 ng/mL versus 23.3% (95%-CI: 1.0-63.2) when >1.04 ng/mL.
  
  
  METHODS
  Chordoma patients were treated with sorafenib 800 mg/day for 9 months, unless earlier occurrence of progression or toxicities. Six biomarkers (sE-Selectin, VEGF, VEGF-C, placental growth factor (PlGF), Thrombospondin, Stem Cell Factor (SCF)) were measured at baseline (day 1: D1) and day 7 (D7).
  
  
  CONCLUSIONS
  High levels of VEGF was associated with poor outcome.
authors.affiliation: Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
authors.forename: Loic
authors.initials: L
authors.lastname: Lebellec
authors.affiliation: Department of Medical Oncology, Institut Paoli-Calmette, Marseille, France.
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
authors.affiliation: SIRIC OncoLille, Clinical Research and Methodological Platform, Lille, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Tresch-Bruneel
authors.affiliation: Department of Medical Oncology, Centre René Gauducheau, Nantes, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bompas
authors.affiliation: Department of Molecular Pharmacology, Cancer Research Center of Marseille, Institut Paoli Calmettes, Marseille, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Toiron
authors.affiliation: Department of Molecular Pharmacology, Cancer Research Center of Marseille, Institut Paoli Calmettes, Marseille, France.
authors.forename: Luc
authors.initials: L
authors.lastname: Camoin
authors.affiliation: Department of Medical Oncology, Gustave Roussy, Villejuif, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.affiliation: Department of Medical Oncology, Institut Curie, Paris, France.
authors.forename: Valerie
authors.initials: V
authors.lastname: Laurence
authors.affiliation: Clinical Research Unit, Centre Oscar Lambret, Lille, France.|SIRIC OncoLille, Clinical Research and Methodological Platform, Lille, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Clisant
authors.affiliation: Clinical Research Unit, Centre Oscar Lambret, Lille, France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Decoupigny
authors.affiliation: Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.affiliation: Department of Molecular Pharmacology, Cancer Research Center of Marseille, Institut Paoli Calmettes, Marseille, France.
authors.forename: Anthony
authors.initials: A
authors.lastname: Goncalves
authors.affiliation: Department of Medical Oncology, Centre Oscar Lambret, Lille, France.|SIRIC OncoLille, Clinical Research and Methodological Platform, Lille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Penel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002817:Chordoma / Q000097:blood* / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D008565:Membrane Proteins; C098069:PIGF protein, human; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000077157:Sorafenib
keywords: biomarker; chordoma; placental growth factor; sorafenib; vascular endothelial growth factor